Clinical trial NCT00351039 (phase 1/phase 2, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: bevacizumab, erlotinib, pemetrexed
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient must have histologically proven diagnosis of Non-Squamous NSCLC. NSCLC
             histologies that will be included in this trial will be adenocarcinoma, large cell
             carcinoma and adeno-squamous carcinoma. Patients with bronchioloalveolar carcinoma
             (BAC) will be also included in this trial.

          -  Patients must be 70 years of age or older.

          -  Patient must have either stage IIIB disease with malignant pleural effusion or stage
             IV disease. All patients must have measurable disease. Evaluable disease will be
             separately outlined and elucidated.

          -  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of
             either 0 or 1.

          -  Patient must have adequate renal function with a serum creatinine level of less than
             1.5mg/dl and patient should have a calculated creatinine clearance of more than
             45ml/min.

          -  Patient must have adequate hepatic function with a serum bilirubin level of less that
             3mg/dl, and an alkaline phosphatase, Alanine Amino Transferase (ALT) and Aspartate
             Amino Transferase (AST) of less than three times the upper limit of normal

          -  Patient must also have evidence of adequate bone marrow function with an absolute
             neutrophil count of more than 1, 500 cells per deciliter and a platelet count of more
             than 100,000 per deciliter.

          -  Patients must be more than 28 days since prior open biopsy; more than 7 days since
             prior fine-needle aspiration; more than 7 days since prior core biopsy; more than 28
             days since prior surgery.

          -  Patients must be able to take dexamethasone, folic acid and vitamin B-12
             supplementation.

          -  All patients must sign informed consent that will detail the investigational nature of
             the study in accordance with the institutional and federal guidelines.

        Exclusion Criteria:

          -  Lung carcinoma of squamous cell histology or any histology in close proximity to a
             major vessel, with or without cavitation.

          -  Patients with hypercalcemia (corrected calcium of more than 11 mg/dl) will be
             excluded.

          -  Patients with history of hemoptysis, hematemesis, coagulopathy or thrombosis will be
             excluded.

          -  Patients requiring anticoagulation for any reason will be excluded.

          -  Patients who recently have an acute infection.

          -  History of palliative radiation therapy within 2 weeks.

          -  Blood pressure of >150/100 Millimeter Mercury(mmHg).

          -  Currently ongoing unstable angina.

          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure.

          -  History of myocardial infarction within 6 months.

          -  History of stroke within 6 months.

          -  Clinically significant peripheral vascular disease.

          -  Presence of central nervous system or brain metastases.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 0, anticipation of need for major surgical procedure during the course of
             the study.

          -  Minor surgical procedures such as fine needle aspirations or core biopsies within 7
             days prior to Day 0.

          -  Pregnant (positive pregnancy test) or lactating.

          -  Urine calculated creatinine clearance of less than 45ml/minute and a urinary protein.
             Creatinine ratio of more than 1.

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to Day 1.

          -  Serious, non-healing wound, ulcer, or bone fracture.

          -  Inability to comply with study and/or follow-up procedures.